Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)

Keros Therapeutics (KROS) has 3 years of Other Non-Current Liabilities data on file, last reported at $16000.0 in Q3 2021.

• For the quarter ending Q3 2021, Other Non-Current Liabilities fell 79.22% year-over-year to $16000.0; the trailing twelve-month figure through Sep 2021 stood at $16000.0 (down 79.22% YoY), and the FY2020 full-year result was $62000.0, down 47.9% from the prior year.
• Other Non-Current Liabilities for Q3 2021 stood at $16000.0, down from $32000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $119000.0 in Q4 2019 and bottomed at $16000.0 in Q3 2021.
• The 3-year median for Other Non-Current Liabilities is $69500.0 (2020), against an average of $68500.0.
• The widest annual swing landed in 2020, when Other Non-Current Liabilities sank 47.9%; it then tumbled 79.22% in 2021.
• A 3-year view of Other Non-Current Liabilities shows it stood at $119000.0 in 2019, then plunged by 47.9% to $62000.0 in 2020, then sank by 74.19% to $16000.0 in 2021.
• The last three Other Non-Current Liabilities figures came in at $16000.0 (Q3 2021), $32000.0 (Q2 2021), and $47000.0 (Q1 2021), per Business Quant data.

Peer Comparison